A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model - Report - MDSpire
Advertisement
A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model
Clinical Report: Immunogenicity of a Conjugate Vaccine Targeting Chlamydia trachomatis
Overview
This study evaluates the immunogenicity of a novel conjugate vaccine targeting Chlamydia trachomatis in a porcine model. The CPAF-STG1151 conjugate vaccine demonstrated the most robust systemic T cell response compared to other formulations, highlighting its potential as an effective vaccine candidate.
Background
Chlamydia trachomatis is the leading cause of bacterial sexually transmitted infections worldwide, often leading to severe reproductive health complications. Current screening and treatment methods are insufficient, and the absence of a licensed vaccine underscores the need for effective immunization strategies. The porcine model offers a relevant platform for vaccine development due to its physiological similarities to humans.
Data Highlights
Vaccine Candidate
Response Type
Key Findings
CPAF-STG1151
Systemic T cell reaction
Most potent response with IFNγ production
CPAF/NanoST
Cell-mediated immune response
Moderate response
CPAF/IMS1313
Traditional adjuvant
Lower response compared to CPAF-STG1151
Key Findings
The CPAF-STG1151 conjugate vaccine elicited the strongest systemic T cell response.
All T cell subsets (CD4, CD8, and γδ T cells) contributed to the immune response.
Method of administration (intramuscular vs. intradermal) did not significantly affect immune response intensity.
Highest anti-CPAF IgG serum concentrations were observed with the CPAF-STG1151 vaccine.
The study supports the potential of STING pathway agonists as effective vaccine adjuvants.
Clinical Implications
The findings suggest that the CPAF-STG1151 vaccine candidate could be a promising approach to induce a robust immune response against Chlamydia trachomatis. Further research is warranted to explore mucosal delivery methods and assess the vaccine's effectiveness in clinical settings.
Conclusion
The development of the CPAF-STG1151 conjugate vaccine represents a significant advancement in the pursuit of an effective vaccine against Chlamydia trachomatis. Continued evaluation in preclinical models is essential for future clinical applications.
by Leonie Bettin, Christine Unterweger, Maximiliane Dippel, Tamara Borysova, Maria Stadler, Jonathan Harris, James Rozzelle, Daisy Arroyo, Jeff Fairman, Taylor B. Poston, Eric Perouzel, Thierry Lioux, Juan F. Hernandez-Franco, Harm HogenEsch, Andrea Buzanich-Ladinig, Toni Darville, Tobias Käser
